Rollins, Rentokil, and Ecolab operate in pest control and sanitation services with contracts that renew reliably, providing steady income despite volatile stock prices. Rollins saw a 7.9% revenue increase but its stock dropped nearly 50% in 2026 due to weaker one-time jobs and residential leads. Rentokil reported improved customer retention and pricing above inflation but faced termite damage liabilities, causing its shares to fall 28% this year. Ecolab, with diverse sanitation services, raised its dividend and earnings guidance, benefiting from stable contract renewals and pricing power despite input cost pressures. These companies’ recurring revenue models offer resilience even when market sentiment is weak, making retention and pricing key metrics to watch going forward.
The story covers Rollins, Rentokil, and Ecolab, companies known for steady income through recurring contracts. For readers following consumer cyclical stocks, here is Pluang's market snapshot as of Sep 28, 2026 19:31 WIB: out of 112 priced US stocks in the sector, 23 rose and 72 fell today. Among notable movers, NIO gained 1.40% to USD 3.63 with a typical hold time of 81 days, while Carnival Corp declined 1.39% to USD 21.94 with a longer hold time of 106 days, and Carvana Co dropped 1.31% to USD 64.21 with a shorter hold time of 28 days.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
